Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Chromosome 1p deletion is a chromosome abnormality that occurs when there is a missing copy of the genetic material located on the short arm (p) of chromosome 1. The severity of the condition and the signs and symptoms depend on the size and location of the deletion and which genes are involved. Features that often occur in people with chromosome 1p deletion include developmental delay, intellectual disability, behavioral problems, and distinctive facial features. Most cases are not inherited, but people can pass the deletion on to their children. Treatment is based on the signs and symptoms present in each person.
Biomarker and diagnostic research for partial deletion of the short arm of chromosome 1 has been reported in the published literature.
No clinical trials have been registered for partial deletion of the short arm of chromosome 1.
56 publications have been identified in PubMed for partial deletion of the short arm of chromosome 1. Research spans Diagnostic / Biomarker (30%), Basic Science / Preclinical (23%), and Review / Meta-Analysis (16%).
Research Type | Count | % of Total |
|---|---|---|
Testing and diagnosis research | 17 | 30% |
Data assembled from 3 of 12 sources · Last updated Sep 21, 2026, 6:35 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Laboratory research |
13 |
23% |
Research summaries | 9 | 16% |
Patient case studies | 8 | 14% |
Disease patterns and progression | 6 | 11% |
Other research | 2 | 4% |
Clinical study results | 1 | 2% |
Han C (2027). [PMID: 42115062](https://pubmed.ncbi.nlm.nih.gov/42115062/). *Lancet Digit Health*. [Basic Science / Preclinical]
Saakyan SV (2026). [PMID: 41847805](https://pubmed.ncbi.nlm.nih.gov/41847805/). *Vestn Oftalmol*. [Epidemiology / Natural History]
Yüksel Ülker A (2026). [PMID: 42217266](https://pubmed.ncbi.nlm.nih.gov/42217266/). *Brain Dev*. [Epidemiology / Natural History]
Farahani S (2026). [PMID: 40817944](https://pubmed.ncbi.nlm.nih.gov/40817944/). *Eur Radiol*. [Review / Meta-Analysis]
Paterra R (2026). [PMID: 41792855](https://pubmed.ncbi.nlm.nih.gov/41792855/). *Acta Neuropathol Commun*. [Diagnostic / Biomarker]
van den Bent MJ (2026). [PMID: 41449147](https://pubmed.ncbi.nlm.nih.gov/41449147/). *Lancet Oncol*. [Clinical Trial Publication]
Ozono I (2026). [PMID: 41189118](https://pubmed.ncbi.nlm.nih.gov/41189118/). *Jpn J Clin Oncol*. [Diagnostic / Biomarker]
He W (2026). [PMID: 41308577](https://pubmed.ncbi.nlm.nih.gov/41308577/). *Eur J Radiol*. [Diagnostic / Biomarker]
Kabadayi ED (2026). [PMID: 41553164](https://pubmed.ncbi.nlm.nih.gov/41553164/). *Clin Neuropathol*. [Basic Science / Preclinical]
Udutha S (2026). [PMID: 41863390](https://pubmed.ncbi.nlm.nih.gov/41863390/). *Neuro Oncol*. [Basic Science / Preclinical]